The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk

Abstract Background: The apolipoprotein B (apoB)/apoA-I ratio represents the balance of proatherogenic and antiatherogenic lipoproteins. The purpose of this study was to determine whether the apoB/apoA-I ratio was superior to any of the cholesterol ratios – total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C), low-density lipoprotein cholesterol (LDL-C)/HDL-C and non-HDL-C/HDL-C – in predicting the risk of coronary disease. Moreover, we examined whether any lipids, lipoproteins or cholesterol ratios add significant predictive information beyond that provided by the apoB/apoA-I ratio. Methods: Plasma lipids, lipoproteins, apoB, and apoA-I were measured in 69,030 men and 57,168 women above 40years of age. After a mean follow-up of 98months, 1183 men and 560 women had died from a myocardial infarction in this prospective apolipoprotein-related mortality risk (AMORIS) study. Results: High apoB and a high apoB/apoA-I ratio were strongly related to increased coronary risk, while high apoA-I was inversely related to risk. The apoB/apoA-I ratio was superior to any of the cholesterol ratios in predicting risk. This advantage was most pronounced in subjects with LDL-C levels <3.6mmol/l. Addition of lipids, lipoproteins or any cholesterol ratio to apoB/apoA-I in risk models did not further improve the strong predictive value of apoB/apoA-I. Conclusions: These results indicate that the apoB/apoA-I ratio is at present the best single lipoprotein-related variable to quantitate coronary risk. Given the additional advantages apolipoproteins possess – fasting samples are not required, apoB/apoA-I is a better index of the adequacy of statin therapy than LDL-C, and the measurement of apoB and apoA-I are standardized, whereas LDL-C and HDL-C are not – there would appear to be considerable advantage to integrating apolipoproteins into clinical practice.

[1]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[2]  G. Dagenais,et al.  Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. , 1996, Circulation.

[3]  F. P. Anderson,et al.  Performance of four homogeneous direct methods for LDL-cholesterol. , 2002, Clinical chemistry.

[4]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[5]  D R Shapiro,et al.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, Circulation.

[6]  A. Evans,et al.  Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[7]  A. Moss,et al.  Thrombogenic factors and recurrent coronary events. , 1999, Circulation.

[8]  M. Carroll,et al.  Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). , 1997, Clinical chemistry.

[9]  A. Sniderman,et al.  Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.

[10]  J. Frohlich,et al.  Coronary artery disease in patients at low risk--apolipoprotein AI as an independent risk factor. , 2001, Atherosclerosis.

[11]  W. März,et al.  The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations , 2001, Clinical chemistry and laboratory medicine.

[12]  J. Otvos.  Why Cholesterol Measurements May be Misleading about Lipoprotein Levels and Cardiovascular Disease Risk – Clinical Implications of Lipoprotein Quantification Using NMR Spectroscopy , 2002 .

[13]  S. Grundy.  Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. , 2002, Circulation.

[14]  M. Davidson.  Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. , 2004, The American journal of cardiology.

[15]  S. Marcovina,et al.  Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group. , 1998, Clinical chemistry.

[16]  W. Cromwell,et al.  Measurement issues related to lipoprotein heterogeneity. , 2002, The American journal of cardiology.

[17]  Richard M. Moe,et al.  Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. , 2004, Journal of the American College of Cardiology.

[18]  I. Holme,et al.  Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. , 1998, Clinical chemistry.

[19]  W. H. Hannon,et al.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. , 1994, Clinical chemistry.

[20]  R. Krauss,et al.  Metabolic origins and clinical significance of LDL heterogeneity DOI 10.1194/jlr.R200004-JLR200 , 2002, Journal of Lipid Research.

[21]  P. Barter,et al.  Molecular mechanisms of reverse cholesterol transport , 1996, Current opinion in lipidology.

[22]  D. Yach,et al.  Research gap in cardiovascular disease in developing countries , 2003, The Lancet.

[23]  G. Dagenais,et al.  The role of the cardiovascular specialist in the prevention of cardiovascular diseases - executive summary. , 1999, Canadian Journal of Cardiology.

[24]  Steven Hawken,et al.  Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .

[25]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[26]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.

[27]  A. Keech,et al.  Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment , 2003, The Lancet.

[28]  I. Holme,et al.  Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43 000 Swedish males and females , 1992, International journal of clinical & laboratory research.

[29]  J. Frohlich,et al.  Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. , 2003, Clinical biochemistry.

[30]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2004, European heart journal.

[31]  A. Sniderman.  Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm , 2004, Current opinion in lipidology.

[32]  M. Okazaki,et al.  Differential reactivity of two homogeneous LDL-cholesterol methods to LDL and VLDL subfractions, as demonstrated by ultracentrifugation and HPLC. , 2002, Clinical chemistry.

[33]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[34]  G. Walldius,et al.  Apolipoprotein B and apolipoprotein A‐I: risk indicators of coronary heart disease and targets for lipid‐modifying therapy , 2004, Journal of internal medicine.

[35]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[36]  E. Hawe,et al.  Nonfasting Apolipoprotein B and Triglyceride Levels as a Useful Predictor of Coronary Heart Disease Risk in Middle-Aged UK Men , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[37]  R. McPherson,et al.  Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[38]  S. Haffner,et al.  Comparison of the Associations of Apolipoprotein B and Low-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in the Insulin Resistance Atherosclerosis Study (IRAS) , 2003, Circulation.

[39]  W. H. Hannon,et al.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. , 1993 .

[40]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .